
Henry Schein (HSIC) Stock Forecast & Price Target
Henry Schein (HSIC) Analyst Ratings
Bulls say
Henry Schein Inc. has demonstrated steady revenue growth across its various segments, with medical products revenue increasing by 4.7% and dental business revenue rising by 2.7%, signaling a solid demand for healthcare solutions. The global technology segment significantly contributed to this growth, generating $173 million in revenue and achieving a notable 9.7% increase, reflecting the company's effective integration of technology within its service offerings. Additionally, the anticipated mid-single digit growth in adjusted EBITDA for 2025 indicates a strong operational performance and financial health moving forward.
Bears say
Henry Schein Inc. reported a gross margin of 30.7%, falling short of the 31.6% expectation, primarily due to an unfavorable mix in its distribution and specialty products businesses, indicating challenges in maintaining profitability. Although the company experienced a slight increase in revenue in its Global Distribution and Value-Added Services segment, it remained below expectations, raising concerns about its growth trajectory in a competitive market. Furthermore, while adjusted EBITDA surpassed expectations, the overall performance metrics, including the decline in gross margin, suggest underlying weaknesses that may negatively impact long-term investor confidence in the stock.
This aggregate rating is based on analysts' research of Henry Schein and is not a guaranteed prediction by Public.com or investment advice.
Henry Schein (HSIC) Analyst Forecast & Price Prediction
Start investing in Henry Schein (HSIC)
Order type
Buy in
Order amount
Est. shares
0 shares